This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Neomycin sulfate with polymyxin and hydrocortisone auricular


Ear drops containing neomycin sulfate, polymyxin and hydrocortisone

Drugs List

  • OTOSPORIN ear drops
  • polymyxin b 10000unit/ml and neomycin 3400unit/ml and hydrocortisone 1% ear drops
  • Therapeutic Indications


    Otitis externa - infective



    Instil 3 drops into the auditory canal of the affected ear three or four times daily.


    Instil 3 drops into the auditory canal of the affected ear three or four times daily.


    Children over 3 years
    Instil 3 drops into the auditory canal of the affected ear three or four times daily.

    Additional Dosage Information

    Alternatively, a gauze wick may be placed into the external auditory canal and kept saturated with the solution. The wick may be left in the auditory canal for 24 to 48 hours.


    Children under 3 years
    Suspected tympanic membrane perforation
    Uncontrolled systemic infection
    Perforated tympanic membrane

    Precautions and Warnings

    Renal impairment

    Reduce dose in patients with renal impairment
    Not to be used in the immediate pre and post operative period
    Avoid contact with eyes
    Prolonged topical application may cause sensitisation reactions
    Avoid prolonged use
    Advise patient not to exceed stated dose
    Advise patient to see doctor if symptoms persist for 7 days with treatment

    Pregnancy and Lactation


    Neomycin sulfate with polymyxin and hydrocortisone is contraindicated in pregnancy.

    Ototoxicity is known to occur with oral, topical and parenteral neomycin but this has not been reported as an effect in utero. Eighth cranial nerve toxicity in the foetus is known following exposure to kanamycin and streptomycin and may potentially occur with neomycin. No evidence was found in 30 mother-child pairs having 1st trimester exposure to neomycin to suggest a relationship with malformations. There is no detectable teratogenic risk of structural defects for any of the aminoglycoside antibiotics following a case-control pair analysis for 2nd and 3rd month of gestation (Briggs 2015).

    The manufacture notes that use of this product is not recommended.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Neomycin sulfate with polymyxin and hydrocortisone is contraindicated in breastfeeding.

    No information is available from studies or from case reports in breastfeeding women. The manufacturer notes that use of this product in breastfeeding is not recommended.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Burning sensation (local)
    Eczematous reactions

    Further Information

    Last Full Review Date: March 2017

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    Summary of Product Characteristics: Otosporin Ear Drops. Phoenix Labs. Revised March 2015.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.